Table 2.
Fmoc-based PEG-derivatized dual-functional micellar systems.
| PEG-derivatized micellar carriers | Hydrophobic segment | Co-loaded drug | Drug loading capacity | Drug loading efficiency | References |
|---|---|---|---|---|---|
| PEG5K-Fmoc-VE2 | Vitamin E | Doxorubicin | 39.9% | 79.5% | (Lu et al., 2014c) |
| PEG5K-(Fmoc-VE)2 | Vitamin E | Paclitaxel | 20.8% | 80.7% | (Zhang et al., 2014i) |
| PEG5K-Fmoc-VE2 | Vitamin E | Camptothecin | 9.2% | 70.5% | (Lu et al., 2015) |
| PEG5K-Fmoc-FTS2 | S-trans,transfarnesylthiosalicylic acid | Paclitaxel Doxorubicin |
12.1% 32.8% |
55.4% 69.7% |
(Zhang et al., 2014f) |
| PEG5K-Fmoc-S-S-FTS2 | S-trans,transfarnesylthiosalicylic acid | Paclitaxel | 34.0% | 53.5% | (Xu et al., 2017) |
| PEG-Fmoc-GA | Glycyrrhizic acid | Doxorubicin | 7.3% | 93.2% | (Yang et al., 2018b) |
| PEG2K-Fmoc-NLG | NLG919 | Paclitaxel | 24.7% | – | (Chen et al., 2016) |
| PEG2K-Fmoc-NLG | NLG919 | Paclitaxel | 5.6% | 98.3% | |
| Sunitinib | 8.0% | 96.4% | (Chen et al., 2018) | ||
| PEG2K-Fmoc-NLG | NLG919 | Doxorubicin | 15.6% | 93.6% | (Zhai et al., 2017) |
| PEG2K-Fmoc-Ibu | Ibuprofen | Paclitaxel | 67.3% | 88.4% | (Zhao et al., 2016) |